SUMM Summit Therapeutics Plc

 
TIDMSUMM 
 
   Summit Therapeutics plc 
 
   ('Summit' or the 'Company') 
 
   Summit Therapeutics to Participate in Upcoming Investor Conferences 
 
   Oxford, UK, and Cambridge, MA, US, 4 September 2019 -- Summit 
Therapeutics plc (NASDAQ: SMMT, AIM: SUMM), a leader in new mechanism 
antibiotic innovation, announces that management will participate in 
several upcoming investor conferences taking place in New York City. 
 
 
   -- 9 September 2019 -- Janney Healthcare Conference 
 
   -- 10 September 2019 -- H.C. Wainwright 21st Annual Global Investment 
      Conference, presentation at 12:05pm EDT 
 
   -- 23-24 September 2019 -- Oppenheimer Fall Summit 
 
 
   A live webcast of the H.C. Wainwright presentation will be available in 
the Investors section of the Company's website, 
https://www.globenewswire.com/Tracker?data=cyMVCwwtbGCy0uOxLsyaeiOIz4R7OeGBS-vAW-HEGoqtd-tDF2jRKxpmTZK9i1puaYReD7yfUEQ-pCMfBds7WDWLJcqMdWWC3xCHR9f9fPg= 
www.summitplc.com. A replay of the webcast will be available from the 
same location soon after the live presentation. There will be no podium 
presentations at the Janney and Oppenheimer conferences. 
 
   About Summit Therapeutics 
 
   Summit Therapeutics is a leader in antibiotic innovation. Our new 
mechanism antibiotics are designed to become the new standards of care 
for the benefit of patients and create value for payors and healthcare 
providers. We are currently developing new mechanism antibiotics for 
infections caused by C. difficile, N. gonorrhoeae and Enterobacteriaceae 
and are using our proprietary Discuva Platform to expand our pipeline. 
For more information, visit www.summitplc.com and follow us on Twitter 
@summitplc. 
 
   Contacts 
 
 
 
 
Summit 
Glyn Edwards / Richard Pye (UK office)     Tel:                  44 (0)1235 443 951 
Michelle Avery (US office)                                          +1 617 225 4455 
 
Cairn Financial Advisers LLP (Nominated 
 Adviser)                                  Tel:                 +44 (0)20 7213 0880 
Liam Murray / Tony Rawlinson 
 
N+1 Singer (Joint Broker)                  Tel:                 +44 (0)20 7496 3000 
Aubrey Powell / Jen Boorer, Corporate 
 Finance 
 Tom Salvesen, Corporate Broking 
 
Bryan Garnier & Co Limited (Joint Broker)  Tel:                 +44 (0)20 7332 2500 
Phil Walker / Dominic Wilson 
MSL Group (US)                             Tel:                     +1 781 684 6557 
                                                         mailto:summit@mslgroup.com 
Jon Siegal                                                      summit@mslgroup.com 
                                                  --------------------------------- 
 
Consilium Strategic Communications (UK)    Tel:                 +44 (0)20 3709 5700 
Mary-Jane Elliott / Sue Stuart / Sukaina          mailto:summit@consilium-comms.com 
 Virji                                             summit@consilium-comms.com 
                                                  --------------------------------- 
Lindsey Neville 
 
 
   -END- 
 
 
 
 

(END) Dow Jones Newswires

September 04, 2019 07:00 ET (11:00 GMT)

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Mar 2024 to Apr 2024

Summit Therapeutics (LSE:SUMM)
Historical Stock Chart
From Apr 2023 to Apr 2024